Literature DB >> 32454051

Severity of negative mood and anxiety symptoms occurring during acute abstinence from tobacco: A systematic review and meta-analysis.

A A Conti1, S Tolomeo2, J D Steele3, A M Baldacchino4.   

Abstract

This review was conducted with the following goals: To quantify the severity of mood and anxiety symptoms emerging during acute abstinence from tobacco (1). To explore sex differences related to the experience of specific symptoms (2). To investigate the early time course of symptoms (3). A meta-analysis was performed from 28 studies assessing mood and anxiety symptoms during the earliest phases of tobacco abstinence (up to 24 hrs post-quit) conducted from 1999 to 2019. Results revealed a significant (p < 0.0001) increase in 'anxiety', 'anger/irritability', 'depressed mood /sadness', and composite negative affect ('NA') in the 24 hours following smoking cessation. The largest effect size was detected for 'anxiety' (0.63). A qualitative analysis was performed to investigate sex differences and the time course of the specific symptoms. Results indicated that female smokers may experience worse mood symptoms compared to male smokers and that these symptoms may emerge within 3 hrs post-quit. Smoking cessation programs should implement sex-tailored interventions in order to improve their effectiveness, while future research should focus on alternative methods of nicotine administration.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Acute abstinence; Anger; Anxiety; Depression; Meta-analysis; Mood; Negative affect; Nicotine; Tobacco; Withdrawal

Mesh:

Year:  2020        PMID: 32454051     DOI: 10.1016/j.neubiorev.2020.04.018

Source DB:  PubMed          Journal:  Neurosci Biobehav Rev        ISSN: 0149-7634            Impact factor:   8.989


  3 in total

1.  Chronic exposure to cigarette smoke extract upregulates nicotinic receptor binding in adult and adolescent rats.

Authors:  Michelle Cano; Daisy D Reynaga; James D Belluzzi; Sandra E Loughlin; Frances Leslie
Journal:  Neuropharmacology       Date:  2020-09-17       Impact factor: 5.250

Review 2.  Novel Pharmacotherapies in Parkinson's Disease.

Authors:  Yousef Tizabi; Bruk Getachew; Michael Aschner
Journal:  Neurotox Res       Date:  2021-05-18       Impact factor: 3.911

Review 3.  Nicotine and the nicotinic cholinergic system in COVID-19.

Authors:  Yousef Tizabi; Bruk Getachew; Robert L Copeland; Michael Aschner
Journal:  FEBS J       Date:  2020-08-25       Impact factor: 5.622

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.